The possibility that the primary activity of Gal-3C in the in vivo model may be mediated by interactions involving the tumor environment rather than by direct cytotoxicity to the MM cells is supported by our finding that the modest sensitivity of the MM cells to Gal-3C did not appear to depend on their galectin-3 expression levels. The gene discussed is LGALS3; the disease is Miyoshi myopathy.